PortalPublikationenEffect of bortezomib on EGFR expression in head and neck squ...

Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.

Standard

Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines. / Wagenblast, Jens; Hambek, Markus; Baghi, Mehran; Knecht, Rainald.

in: ANTICANCER RES, Jahrgang 28, Nr. 2, 2, 2008, S. 687-692.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wagenblast, J, Hambek, M, Baghi, M & Knecht, R 2008, 'Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.', ANTICANCER RES, Jg. 28, Nr. 2, 2, S. 687-692. <http://www.ncbi.nlm.nih.gov/pubmed/18507008?dopt=Citation>

APA

Wagenblast, J., Hambek, M., Baghi, M., & Knecht, R. (2008). Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines. ANTICANCER RES, 28(2), 687-692. [2]. http://www.ncbi.nlm.nih.gov/pubmed/18507008?dopt=Citation

Vancouver

Wagenblast J, Hambek M, Baghi M, Knecht R. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines. ANTICANCER RES. 2008;28(2):687-692. 2.

Bibtex

@article{6d95861c8f244aaaa0973fa3098e6f27,
title = "Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.",
abstract = "BACKGROUND: Overexpression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC) has often been correlated with poor prognosis. Recent investigations have shown that the proteasome inhibitor bortezomib exhibits a high antiproliferative and apoptotic activity in HNSCC cell lines. The present study investigated whether bortezomib has an effect on EGFR expression in different squamous cell carcinoma cell lines. MATERIALS AND METHODS: Six EGF-stimulated or non-stimulated squamous carcinoma cell lines were treated with bortezomib. Western blots were performed to determine EGFR expression. For statistical analysis, a Wilcoxon test for matched pairs (dependent samples) was performed using SPSS 13.0 software for Windows. RESULTS: Changes in EGFR expression after bortezomib treatment in EGF non-stimulated and EGF-stimulated squamous carcinoma cell lines failed to reach statistical significance in either experimental group (p > 0.05). CONCLUSION: Given the high expression of EGFR in head and neck tumors, further investigations should address the question whether the apoptotic activity of bortezomib can be enhanced by adding an anti-EGFR antibody.",
author = "Jens Wagenblast and Markus Hambek and Mehran Baghi and Rainald Knecht",
year = "2008",
language = "Deutsch",
volume = "28",
pages = "687--692",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

RIS

TY - JOUR

T1 - Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.

AU - Wagenblast, Jens

AU - Hambek, Markus

AU - Baghi, Mehran

AU - Knecht, Rainald

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Overexpression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC) has often been correlated with poor prognosis. Recent investigations have shown that the proteasome inhibitor bortezomib exhibits a high antiproliferative and apoptotic activity in HNSCC cell lines. The present study investigated whether bortezomib has an effect on EGFR expression in different squamous cell carcinoma cell lines. MATERIALS AND METHODS: Six EGF-stimulated or non-stimulated squamous carcinoma cell lines were treated with bortezomib. Western blots were performed to determine EGFR expression. For statistical analysis, a Wilcoxon test for matched pairs (dependent samples) was performed using SPSS 13.0 software for Windows. RESULTS: Changes in EGFR expression after bortezomib treatment in EGF non-stimulated and EGF-stimulated squamous carcinoma cell lines failed to reach statistical significance in either experimental group (p > 0.05). CONCLUSION: Given the high expression of EGFR in head and neck tumors, further investigations should address the question whether the apoptotic activity of bortezomib can be enhanced by adding an anti-EGFR antibody.

AB - BACKGROUND: Overexpression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC) has often been correlated with poor prognosis. Recent investigations have shown that the proteasome inhibitor bortezomib exhibits a high antiproliferative and apoptotic activity in HNSCC cell lines. The present study investigated whether bortezomib has an effect on EGFR expression in different squamous cell carcinoma cell lines. MATERIALS AND METHODS: Six EGF-stimulated or non-stimulated squamous carcinoma cell lines were treated with bortezomib. Western blots were performed to determine EGFR expression. For statistical analysis, a Wilcoxon test for matched pairs (dependent samples) was performed using SPSS 13.0 software for Windows. RESULTS: Changes in EGFR expression after bortezomib treatment in EGF non-stimulated and EGF-stimulated squamous carcinoma cell lines failed to reach statistical significance in either experimental group (p > 0.05). CONCLUSION: Given the high expression of EGFR in head and neck tumors, further investigations should address the question whether the apoptotic activity of bortezomib can be enhanced by adding an anti-EGFR antibody.

M3 - SCORING: Zeitschriftenaufsatz

VL - 28

SP - 687

EP - 692

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 2

M1 - 2

ER -